SULFAMETHOXAZOLE AND TRIMETHOPRIM clinical trials
6 indexed studies · 0 currently recruiting
- AuthorisedTherapeutic exploratory (Phase II)
A multi-center single arm Phase II study to evaluate the safety and efficacy of genetically engineered autologous cells expressing anti-CD20 and anti-CD19 specific chimeric antigen receptor in subjects with relapsed and/or refractory diffuse large B cell lymphoma
This study looks at a new type of cell therapy, called MB-CART2019.1, for people with a specific type of lymphoma that has come back or hasn't responded to other treatments. It checks how safe and effective it is.
For: Relapsed/refractory diffuse large B cell lymphoma (R-R DLBCL)Hungary · Croatia - AuthorisedTherapeutic use (Phase IV)
Evaluation of the clinical implementation of biofilm susceptibility to antibiotics using Minimum Biofilm Eradication Concentration (MBEC) in addition to Minimum Inhibitory Concentration (MIC) to guide the treatment of periprosthetic joint infections; a prospective randomized clinical trial
This study looks at how best to treat infections around artificial hip or knee joints. It compares standard test results with a new test to see if combining them helps doctors choose better antibiotics and leads to fewer repeat infections or surgeries.
For: Periprosthetic hip joint infection Periprosthetic knee joint infectionSweden - AuthorisedTherapeutic confirmatory (Phase III)
PYELOCOURT - 3-day intravenous antibiotic treatment versus 3-day intravenous followed by 7-day oral antibiotic treatment for acute pyelonephritis in children 1 month to 3 years old: a non-inferiority open randomized multicentric clinical trial
This study looks at how best to treat kidney infections in children aged 1 month to 3 years. It compares a 3-day IV antibiotic with a 3-day IV followed by a 7-day oral antibiotic. The main goal is to see which treatment best prevents the infection from coming back.
For: acute pyelonephritis (AP) in childrenFrance - AuthorisedTherapeutic use (Phase IV)
TIME-TO-LIA : Optimal Duration of Antibiotic Therapy in Drained Pyogenic Liver Abscess: 3 weeks versus 6 weeks, a non-inferiority trial
This study is looking at the best length of antibiotic treatment for liver abscesses, comparing 3 weeks to 6 weeks. It wants to see if shorter treatment is just as effective and safe as longer treatment for patients after their abscess has been drained.
For: Pyogenic liver abscessFrance - AuthorisedTherapeutic use (Phase IV)
Defining Antibiotic Levels in Intensive care patients (DALI-2) protocol - A multi-national pharmacokinetic/pharmacodynamic cohort study to determine whether contemporary antibiotic dosing for critically ill patients achieves therapeutic exposures.
This study looks at how well antibiotics work in very sick patients. Researchers want to make sure these important medicines reach the right levels in the body to fight serious infections effectively and safely. It's about getting the dose just right.
For: Serious infections in critically ill patients treated with antibioticsFrance - AuthorisedTherapeutic exploratory (Phase II)
The HIt HArd and hiT early in multiple sclerosis trial – HiHat trial
This study, called HiHat, is looking into new treatments for relapsing-remitting multiple sclerosis (MS) in people who have had the condition for less than 10 years. It's investigating if certain medicines can stop MS from getting worse, while making sure they are safe.
For: Patients with relapsing-remitting multiple sclerosis with less than 10 years disease duration.Sweden